GlassScriptPhysician profile
Kari J Ernst
NPI 1932464971
$3,786.90
in general payments reported to CMS, 2019-2025
15 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $72.46 · 2023: $342 · 2024: $473 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,921 · Food and Beverage: $1,278 · Travel and Lodging: $253 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,921.00 |
| Food and Beverage | $1,278.23 |
| Travel and Lodging | $253.00 |
| Education | $117.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,338.59 | 2024-2025 | Entyvio |
| Janssen Biotech, INC. | $626.85 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $450.15 | 2022-2025 | |
| Medtronic, INC. | $86.38 | 2023 | Interstim |
| Aimmune Therapeutics, INC. | $48.32 | 2024 | |
| Daiichi Sankyo INC. | $37.40 | 2023 | Injectafer |
| Novo Nordisk INC | $32.27 | 2025 | |
| Fresenius Kabi USA, LLC | $31.93 | 2024 | Idacio |
| Amgen INC. | $26.90 | 2023 | Amjevita |
| Genentech USA, INC. | $25.30 | 2022-2023 | Ocrevus |
| Ardelyx, INC. | $22.28 | 2022 | |
| Madrigal Pharmaceuticals | $19.99 | 2025 | Rezdiffra |
| Pfizer INC. | $17.89 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.41 | 2023 | Dupixent |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Ernst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.